Yet in clinics across the country, talented medical professionals are spending hours each day buried in administrative work: updating records, managing appointments manually, writing prescriptions by hand, and sorting through files.

It’s not just inefficient — it’s exhausting.

But what if that could change?

What if you could spend more time caring for patients, and less time wrestling with paperwork?

The Admin Burden Is Real

For every patient seen, there are dozens of backend tasks:

• Scheduling and rescheduling appointments
• Recording and storing patient histories
• Writing and tracking prescriptions
• Managing invoices and receipts
• Following up on missed visits
• Handling compliance and documentation

This creates a double burden:
Time lost on admin tasks
Risk increased due to manual errors and inefficiencies

And let’s not forget — when doctors are distracted by admin, patient care suffers.

GoWello: Turning Chaos Into Care

GoWello is not just a software—it’s a digital ally for the modern healthcare provider.

This AI-powered, all-in-one platform was built to transform how clinics operate, starting with one clear goal: less paperwork, more care.

Here’s how GoWello helps:

Digital Patient Records at Your Fingertips

No more sifting through paper files. With GoWello, every patient’s history, lab results, prescriptions, and follow-ups are stored securely and accessed instantly.

E-Prescriptions Done Right

Say goodbye to handwritten slips and confusion at the pharmacy. Generate, share, and track digital prescriptions in seconds.

Smart Scheduling & Reminders

Automated appointment bookings, follow-up reminders, and real-time availability — no human intervention needed.

Integrated Billing & Invoicing

Create and manage bills directly within the platform, reducing paperwork and speeding up collections.

Time-Saving Templates & Notes

Use reusable consultation templates and AI-suggested notes to record visits faster and more accurately.

The Real Impact

Clinics using GoWello have reported:

• A 60–80% reduction in manual paperwork
• Up to 6 hours saved per week per doctor
• Significant drop in errors and redundancies
• A more relaxed, focused, and productive environment

But the biggest win? More meaningful time with patients.

Go Paperless. GoWello.

By cutting down on paperwork, doctors regain the time and mental space to do what they’re best at: providing quality care.

And in a world that’s moving toward connected, efficient, and digital-first healthcare — GoWello puts you ahead of the curve.

Whether you run a solo practice or a multi-specialty clinic, GoWello adapts to your needs and scales with your growth.

Because when you care less about the files, you care more about the people.

Let’s be honest — even the most skilled doctors and clinic administrators can feel buried under admin work.

But what if there was a way to simplify it all? One platform. Zero hassle. Welcome to GoWello.

Why Patient Management Feels Broken

Most clinics still rely on a mix of disconnected tools — paper forms, Excel sheets, WhatsApp, or outdated software that doesn’t “talk” to each other. This leads to:

• Missed appointments
• Scattered patient records
• Prescription errors
• Delayed follow-ups
• Frustrated staff and unhappy patients

It’s not just inefficient — it’s risky. In today’s digital-first world, patients expect speed, transparency, and continuity. A fractured backend means a fractured experience.

The Case for a Unified Platform

Effective patient management requires integration. Every step — from scheduling to consultation to follow-up — should flow seamlessly. That’s where a modern, all-in-one solution becomes a game-changer.

Enter GoWello: The Future of Patient Management

GoWello is an AI-powered, B2B2C digital healthcare platform designed to bring simplicity, speed, and structure to your clinic operations — with a special focus on streamlining patient care.

Here’s how it works:

Appointment Scheduling Made Effortless

Patients can book online. You get a real-time view of your calendar, automated reminders, and zero no-shows.

Smart, Centralized Patient Records

Access a patient’s full history — prescriptions, consultations, diagnostics — in just a click. No paper. No guesswork.

E-Consulting + In-Clinic = One Unified Workflow

Whether the patient walks in or logs in, their experience remains smooth. GoWello bridges the gap between online and offline seamlessly.

Follow-Up Automation

Get notified when a follow-up is due, send reminders automatically, and never miss a patient touchpoint again.

Integrated Billing & Prescriptions

Generate e-prescriptions and invoices instantly, while reducing manual errors and saving admin time.

AI-Driven Insights

Track metrics like patient retention, appointment trends, and feedback to continually optimize your care delivery.

Real Results from Real Clinics

Clinics using GoWello have reported:

• A 40% increase in patient retention
• A 70% reduction in no-shows
• Admin time savings of 6–8 hours per week
• Happier patients and more relaxed staff

Why It Matters Now More Than Ever

Patients don’t just want medical care anymore — they want a smart experience. From appointment to aftercare, they expect clarity, convenience, and continuity.

GoWello helps you deliver exactly that — without the chaos.

Final Word

Streamlining patient management doesn’t require a tech overhaul — it just needs a smarter solution. With GoWello, you get one platform that does it all, so you can stop juggling tools and start focusing on what truly matters: your patients.

No hassle. No friction. Just seamless care delivery.

It’s clear that the old ways of running a clinic are no longer sustainable. The real question is: what’s the smarter way forward?

The Rise of Integrated Healthcare Platforms

While digital health has seen massive adoption through teleconsultations, most clinics still run on disconnected systems. One tool for video consultations, another for scheduling, another for prescriptions, and yet another for billing.

This patchwork approach leads to data silos, duplicate work, and missed opportunities to deliver seamless care.

That’s where integration becomes a game-changer.

By bringing e-consulting and clinic management onto a single platform, healthcare providers can achieve:

• Streamlined operations with fewer touchpoints and reduced manual work
• Better patient experiences through connected care journeys
• Smarter decision-making using real-time insights and AI-driven tools
• Higher revenue potential due to improved efficiency and reduced leakages

But not all solutions are created equal. That’s where GoWello steps in.

Meet GoWello: Your All-in-One Digital Healthcare Command Center

GoWello is an AI-powered digital healthcare platform built for modern medical practitioners. Unlike standalone tools, GoWello combines e-consulting, e-prescriptions, and clinic management into one unified ecosystem.

Here’s how it’s changing the game:

Seamless E-Consulting
 Conduct virtual consultations effortlessly, with secure patient data access, real-time notes, and instant e-prescriptions — all in one window.

Clinic Management, Simplified
 Automate scheduling, maintain digital patient records, manage billing, and streamline communication without toggling across platforms.

Paperless, Error-Free Prescriptions
 Say goodbye to illegible handwriting and prescription mistakes. With GoWello, AI-assisted e-prescriptions are fast, safe, and fully compliant.

Reduced Admin Load, More Time for Patients
 Doctors using GoWello report saving hours each week on non-clinical tasks — time they now spend on what truly matters: healing.

Affordable, Scalable & Ready for Tomorrow
 Whether you’re a solo practitioner or managing a multi-specialty clinic, GoWello grows with your practice.

Real Results, Real Impact

With GoWello:

• Clinics reduce operational costs by up to 30%
• Physicians save 5–7 hours a week in admin time
• Patient follow-up rates increase by 40% thanks to better engagement tools

It’s not just a platform. It’s a partner in building the future of your practice.

The Bottom Line

Integrating e-consulting and clinic management isn’t a “nice-to-have” anymore — it’s a must-have for forward-thinking healthcare providers. The future is digital, connected, and intelligent. Platforms like GoWello are making that future accessible today.

If you’re still juggling multiple tools and feeling overwhelmed by paperwork, maybe it’s time to let GoWello do the heavy lifting — so you can focus on your patients.

The aim is to provide guidance, says the project brief, “to improve the consistency of local medical devices formularies reflecting the importance of the patient voice in decision making and wider principles of value-based procurement”.

But, fearing that spending reductions are at least part of the reason behind the project, some in industry aren’t convinced, arguing that local formularies (short lists of products and devices recommended as options for prescribers in the local area) risk compromising the right of clinicians to prescribe, and of patients to receive, whichever product on Part IX they consider best meets the needs of the individual patient.

Such restrictions could adversely impact upon patient experiences and outcomes, proving to be a false economy if the move leads to otherwise avoidable complications and/or episodes of treatment.

The project is being driven forward with an unusual air of urgency, kicking off with a call for evidence in early July, and completing with the publication of the new guidance in April 2026, and production, by all local NHS systems (ICSs) in England, of the new formularies by April 2027.

The range of products set to be caught in this new project is very wide, including continence, stoma and wound care; gastrointestinal and urological care; respiratory and airway management; lymphoedema, support and therapeutics; sexual, reproductive and pelvic health; diabetes, glucose monitoring and insulin delivery; oral, dental, ear, eye and nasal care.

Anticipating concerns about the need to avoid unintended consequences for clinicians and patients, the initial project brief does identify a series of issues that will need to be considered.

Those issues include: clinical effectiveness; availability of/access to “real world” evidence; supporting self-care; supporting system savings; reducing health inequalities; supporting patients in living life to the full; appearance, comfort, fit of medical devices; patient choice; diversity of users (including skin colour, those with physical or mental health restrictions, allergies etc.); quality/accessibility of information to help patients choose a device; impact of patient’s personal circumstances; adherence to use of medical devices by patients; accessibility/availability of medical devices; inclusion of medical devices characteristics [learning curve, incremental innovation, dynamic pricing, and organisational impact]in Health Technology Assessments; influence of sex and gender in clinical trials of medical devices; software as a medical device; medical devices used for patient self-testing; medical devices safety.

Industry must proactively engage with this process, as should clinicians, patients and their advocates, and those with expertise in assessing whole system costs when comparing one product with another in the same category. Real world evidence and case studies must be part of the process if patients are not to be adversely affected by an over-reliance on randomised control trials, which are simply not available or feasible for many product categories. The principle that clinicians may prescribe any device listed on Part IX, that they consider most appropriate for their patient, should be highlighted in every formulary and must not be compromised. Med-Tech Insights

These address a critical gap in treating two common fractures. Designed to improve stability, enhance performance, expand surgical options and increase efficiency^4†, both systems feature the same precision threaded locking technology introduced with the original VOLT Platform in 2024.

As President Donald Trump’s tariff policies continue to evolve, medtech investors will be focused on companies’ plans to manage the impact on supply chains when they tune into first-quarter earnings calls starting this week.

Stock prices for some of the sector’s largest companies, such as GE Healthcare and Intuitive Surgical, have come under pressure amid fears about how Trump’s trade wars will affect manufacturers’ businesses.

The tariff plans have brought concerns across industries about the repercussions for global trade. GE Healthcare and Medtronic were among more than 20 U.S. companies that participated in a roundtable meeting last week with China’s Ministry of Commerce.

Expect tariffs to be “highly topical” on first-quarter calls, where companies could discuss how to rejigger manufacturing to match geographies and reduce exposure to tariffs, Morningstar analyst Debbie Wang said in an email.

On Friday, a GE Healthcare spokesperson told MedTech Dive the company would provide an update on the tariff situation on its next earnings call. In February, the company said its 2025 outlook for earnings before interest and tax incorporates an impact from China tariffs of about 10 basis points.

“Our teams are working on potential mitigation plans as these trade policies evolve,” the spokesperson said via email. “Our top priority is to make sure patient and customer deliveries for products and services are not interrupted under any circumstances, while maintaining the best possible quality and cost. This is a dynamic issue.”

Earlier this month, China’s Ministry of Commerce also began an anti-dumping investigation of X-ray tubes from the U.S. and India used in computed tomography machines. A GE Healthcare spokesperson told MedTech Dive at the time that the company did not think the investigation was a material risk to its business in China.

Medtronic is also monitoring global tariff policies and will “continue to assess potential impacts to the company and implement mitigations if necessary,” a spokesperson wrote in an email.

Confusion on reciprocal tariffs

Trump announced a 90-day pause on most reciprocal tariffs last week, in a turnabout from his “Liberation Day” declaration of hefty tariffs on imported goods from most U.S. trading partners. The president also raised total duties on imports from China to 145%. Countries besides China remain subject to a 10% baseline tariff.

Analysts emphasized that the pause on reciprocal tariffs is temporary.

“Despite this 90-day pause, we wouldn’t be surprised if the administration moves forward with implementing tariffs,” said Wang. “However, it’s not clear that any potential reciprocal tariffs would significantly impact the large medical device makers.”

During fourth-quarter calls, device makers including Boston Scientific, Edwards Lifesciences and Zimmer Biomet said the potential impact from tariffs was factored into their full-year guidance ranges. “Most management teams seemed to downplay it as modest to immaterial,” noted Wang.

However, some smaller companies, such as Masimo and Enovis, said during fourth-quarter calls that new tariffs, particularly on products sourced from Mexico, had the potential to affect their financial results.

Intuitive Surgical said in January that a “significant portion” of its instruments are manufactured in Mexico, so tariffs implemented there could have a material effect on the company. However, the company has not yet included a tariff impact in its profit forecast.

J.P. Morgan analyst Robbie Marcus, in a note to clients Monday, wrote that Mexico has been left off of the reciprocal tariffs list for now, but the country is subject to a roughly 25% tariff, with the exception of goods compliant with the United States-Mexico-Canada Agreement.

“We think the worst case scenario has so far been avoided for Intuitive,” Marcus wrote.

RBC Capital Markets analyst Shagun Singh, in an April 3 report, said the implementation of tariffs would likely be an “incremental headwind” to most of the medtech companies the firm covers, as device makers find ways to offset their exposure, with potential impacts beginning to show up in the third quarter and beyond.

The Food and Drug Administration is grappling with a surge in the number of medical devices that contain artificial intelligence or machine learning features. The agency had authorized 882 AI/ML-enabled devices as of March, and many other devices include AI features that don’t require regulatory review.

Currently, AI is most often used in medical devices in the radiology field, although the technology is also used in pathology, for appointment scheduling and in clinical support tools that pull in a variety of metrics.

The influx of AI in medical devices has raised questions from lawmakers and patient safety groups. Medical device industry group Advamed responded to a Congressional request for information on AI in healthcare in May. Advamed said the FDA’s authority is “flexible and robust enough” for AI/ML in medical devices.

On the other hand, patient safety nonprofit ECRI listed insufficient governance of AI in medical technologies among its top health technology hazards for 2024. CEO Marcus Schabacker said AI has the potential to do good, but the technology also can do harm if it provides inaccurate results or magnifies existing inequalities.

MedTech Dive spoke with Schabacker about what developers, regulators and hospital administrators can do to ensure devices that use AI are safe and effective.

This interview has been edited for length and clarity.

MEDTECH DIVE: The FDA finalized guidance in late 2022 on clinical decision support tools, and which ones should be regulated as medical devices. What are your thoughts on that? 

MARCUS SCHABACKER: We think the FDA is taking a much too laissez faire approach here. They should be much more stringent, particularly with decision support tools, and have clear regulations.

If they don’t want to regulate it upfront, they need to put post-market surveillance programs in place at a minimum. But we believe they should be way more forceful in the regulatory pathway and get more evidence from the companies that their tools are truly supportive instead of influencing decisions in a more severe way.

The FDA’s always in a tough spot. On the one hand, they want to make sure that the population stays safe. That’s their mission. That’s our mission too. On the other hand, they want to make sure appropriate innovation can happen and don’t want to be seen as a blocker.

During the early days of the Covid pandemic, Penlon, a then 100% subsidiary of BPL Medical, responded to the Call to Arms by the UK Prime Minister by expressing a keenness to participate in an Emergency Ventilator project. The company submitted the concept of an Emergency Ventilator that would meet the specifications rolled out by the UK MHRA.

Upon an initial interest from the MHRA, Krishnamoorthy swiftly mobilised a core team that would work to create a Ventilator by taking the Minimum Viable Product Approach – which was to evolve an Emergency Ventilator from Penlon’s existing, most popular anaesthesia machine. Penlon’s Emergency Ventilator (ESO2) concept was reviewed by a team of specialists from the NHS, MHRA, Cabinet Office and industry experts from Ford, McLaren, Airbus and Siemens evaluated the manufacturability and scalability of the ESO2 concept on the 21st March 2020 and gave their approval to go ahead and manufacture. Within days, Penlon was given an order to manufacture 5000 units of ES02 Emergency ICU Ventilators (Air Driven Variant), following which another order was placed for a further 10,000 units on March 29, 2020. These units were to be manufactured by Penlon, as a part of the UK Ventilator Challenge consortium. What then unfolded was a demonstration of exceptional leadership skills and commitment to the project by Guru who led a team that developed a final product within a week, where normally development would take several months or years to complete, a statement from BPL Medical Technologies said.

Under Krishnamoorthy’s leadership, Penlon delivered around 11,700 units within 12 weeks, which under normal circumstances would have taken 12 years to manufacture. Moreover, as the project was funded by Public Funds it needed to follow the highest level of frugality and transparency which Guruswamy oversaw personally. The project involved around 4000 staff working round the clock at 5 sites overseen to achieve this historic feat, the statement added.

The UK is showing potential to be a leading example of a nation who puts innovation of medtech first, creating jobs and international trade.

With the National Health Service (NHS) calling for innovation in the space, a pool of homegrown talent and government policies focusing on the ‘right products at the right price,’ the future of medtech in the UK is bright.

The Covid-19 pandemic accelerated innovation in the industry with an increased demand for wearable devices, telemedicine, and integrated artificial intelligence (AI) in medical devices. This year the AI market is predicted to reach sales of $93 billion up 12% from 2022 and in 2019, the wearable device market was worth nearly $27 billion and is expected to grow to $64 billion by 2024. While the telehealth market size was valued at $2.17 billion in 2022.

Mark Oakes, Head of Life Sciences Exports and National Security Lead at the Department for International Trade (DIT) recently addressed the future of UK medtech at the industry event, MedTech Expo 2023 in Birmingham, UK. In his speech, Oakes emphasised the innovation and strength of the UK’s medtech and life sciences sector.

“It’s really impressive to see the innovation and the strength of the UK’s medtech and life sciences sector,” said Oakes. “The industry has also had to withstand the supply chain challenges, inflationary pressures of the last year, which have all added to the business difficulties. These are real challenges that companies are having to navigate and they are not easy to overcome.”

A Promising Outlook:

Despite the challenges, the global market is growing rapidly. According to Oakes, by 2026 medtech revenue is projected to reach $644 billion, presenting significant opportunities for the industry. The UK has earned a global reputation for driving innovation, with over £6.4 billion in exports. Post-Covid, the sector witnessed an increased demand for improved diagnostics, remote patient monitoring, and digital technology in healthcare.

In June 2023 the Health and Social Care Secretary, Steve Barclay announced a £21 million fund for AI technology to diagnose and treat patients quicker.

“Artificial intelligence is already transforming the way we deliver healthcare and AI tools are already making a significant impact across the NHS in diagnosing conditions earlier,” said Barclay. “I’m focused on adopting the latest cutting-edge technology across our health and care system to ensure we can continue to deliver the best care for our patients and cut waiting times, which is one of the government’s five priorities.”

NHS Trusts will be able to apply for an AI Diagnostic Fund to accelerate the distribution of AI imaging and decision support tools diagnosing conditions such as cancers, strokes, and heart conditions. Currently the NHS spends £10 billion a year on medical equipment.

Government support and investment:

The DIT has positioned itself to play a crucial role in supporting medical technology companies. The Department of Business and Trade (DBT) which was established in February 2023 combines the DIT and business support elements of the Department of Business, Energy, and Industrial Strategy. In turn, this allows the UK government to offer end-to-end assistance to the medtech sector including domestic support and international trade.

Addressing the crowd at the MedTech Expo, Oakes explained how the government will support the industry. “Our main objective is to help UK businesses succeed globally by fostering export opportunities, attracting foreign investment, and securing trade deals,” said Oakes. “We work to support UK companies looking to expand into international markets, offering expertise in market research, export strategy development, and navigating trade barriers. We collaborate with foreign governments and international organisations to note negotiate trade agreements that benefit UK businesses.”

An example of this support is already happening across the pond in the US. The UK government has begun forming memorandum of understanding (MOU) agreements on a state-by-state basis. According to Oakes, US states such as Florida have a very strong interest in the life science sector, so establishing these sub national relationships can be beneficial for the UK medtech industry who can target these large and focused economies.

The UK government has also shown its commitment to the sector through strategies and investment packages. The Department of Health and Social Care (DHSC) published its inaugural medtech strategy, outlining the direction and long-term support for the sector. On top of this, a £650 million investment package was revealed which will be used to address key issues impacting the industry. These funding initiatives aim to accelerate clinical trials, improve innovation pathways, and streamline market access, benefiting medtech companies.

Showcasing UK medtech excellence

The DIT is actively promoting the UK MedTech excellence on the international stage. With initiatives such as showcases, competitions, and trade shows providing opportunities for companies to demonstrate their innovations and connect with potential investors and partners.

According to Oakes the DIT will be taking a delegation of UK medical technology businesses to the Kingdom of Saudi Arabia with the purpose of networking with key decision makers in the region. Oakes hopes this opportunity will open to the door for the visiting firms to negotiate potential export prospects and secure possible investments. They will also be attending MEDICA 2023 in Dusseldorf, Germany later in year.

These trips will not only be used to support exports of UK medtech but will also aim to attract inward investment fostering growth for UK companies, especially smaller businesses.

One of the DIT’s most successful export promotion programs is its annual delegations to the Texas Medical Centre. Working with UK Research and Innovation (UKRI) as part of the BioBridge agreement, and in partnership with the Texas Medical Centre, the DIT takes applicants from small and medium-sized enterprises (SME).

“Our five-year partnership has already seen dozens of companies visit Texas and secured over £100 million in export wins,” said Oakes. “It really does work. It’s a great partnership and I’m keen to develop more of those targeted interventions where we can both support investment and explore the critical markets.”

Overcoming challenges:

The path to success for medical technology business includes many obstacles. Reimbursement and regulation remain significant hurdles for companies. However, the UK government has launched initiatives like the Innovation and Devices Access Pathway, designed to streamline the process of introducing new medical technologies into the NHS. Collaborations between NICE, MHRA, Health Technology Wales, and the Scottish Health Technology Group aim to facilitate market access for innovative medical technologies.

Oakes claimed the UK should have confidence in the medtech sector which provides close to 300,000 jobs and accumulates billions in exports. “UK innovations continue to save lives around the world, and this is something companies can be rightly proud of,” said Oakes. “The UK’s medtech sector is not just changing lives; it’s transforming the future of healthcare and its impact resonates globally.”

It comes as the UK government stated that the NHS spent£3 billion on agency staff in 2023 to 2024.

The report noted that during the 2023/24 academic year, 230,000 secondary students across England completed the CEC’s Future Skills Questionnaire (FSQ). It showed that health and social care was one of the most popular career sector choices among Year 11 students. Interest for health and social care has grown steadily in recent years, up 3% since 2022/23.

When viewed regionally, students’ interest in health and social care remains inconsistent, with variability across the country. For instance, only 19% of students in the south-east express interest in a career in the sector, compared to 25% in the north-west. Gender bias was also evident, with female students 3.5% more likely than males to consider a career in healthcare.

The report also noted that depth of awareness of healthcare careers remains shallow. When surveyed, young people were often unable to recall career options available within the NHS beyond more traditional and highly visible roles.

Meanwhile, employers and young people alike recognise that further action is needed to better prepare students for intake. Helping young people understand and prepare for the full range of application processes offers the most scope for improvement, the report noted.

The CEC’s study shows that just over half (54%) of Year 11 students said they knew about different types of recruitment and selection processes. By age 16, young people feel confident in most work-related skills but rate themselves lower on ‘human skills’ vital for health and social care careers like leadership, listening, speaking and teamwork, the report added.

Students from disadvantaged backgrounds are also less confident talking about their skills when applying for courses or jobs. They have career ambitions but are less sure footed when engaging independently with future employers. As one example, only 5% of entrants to medical school are from the lowest socio-economic groups.

The Health Sector Advisory Group has identified and initiated action plans to address barriers locally, using the national careers education system.

One of the steps it advises is to use workplace experiences to deepen young people’s interest in health and social care. Furthermore, it suggested embedding careers awareness about health and social care within the curriculum as well as empowering teachers to help inform students about careers in health and social care.

“Too often, young people who express an interest in working in health and social care are unsure about what pathways are available or feel uncertain about whether they are “the right fit,” Shajeda Ahmed, chief people officer at Black Country Integrated Care Board, said in the report. “Outdated assumptions, limited exposure to real-life experiences, and a lack of personalised guidance all play a role in dampening aspirations or narrowing choices. As a result, too many promising futures are lost before they have the chance to begin.”

Ahmed added that the NHS faces well-documented and significant workforce challenges.

“The NHS Long Term Workforce Plan and the subsequent 10-year strategy outline the scale and urgency of what lies ahead,” Ahmed added. “Solutions will require national coordination and sustained investment, but they also demand innovation and leadership at a local level. One area where we can and must act now is in how we engage young people and support them to consider, prepare for, and progress into health and care careers.”

“This is a wake-up call,” John Yarham, interim CEO of The Careers & Enterprise Company told FE News. “The interest from young people is widespread and growing, but it risks going to waste. We need to come together to create a system that works for students and the NHS, closing the loop between aspiration and opportunity. If we connect the dots between what young people want and what the NHS needs, we won’t just save money, we’ll save lives.”

Jonathan Townsend, UK Chief Executive, The King’s Trust, also commented.

“We know that guidance and work experience to steer young people through the range of career opportunities, combined with dedicated support securing interviews and job offers, transform young people’s confidence and ability to pursue a career in the health and social care sector,” Townsend told FE News.